Novel transcript, antisense to JAG2

This entity represents a natural antisense transcript located opposite the JAG2 gene. Natural antisense transcripts (NATs) are typically non-protein-coding RNAs that play regulatory roles in gene expression. They can regulate their corresponding sense transcripts by a variety of mechanisms, including masking mRNA, modulating alternative splicing, recruiting chromatin modifiers for epigenetic regulation, and facilitating gene silencing or activation[2][3][4]. NATs are widespread in mammalian genomes, participate in key regulatory processes, and some have been implicated in diseases, especially when their regulatory actions affect genes involved in development or cancer. As of now, no direct therapeutic drugs or biomarker roles have been established for ENSG00000303831 and its role is likely regulatory rather than as a primary therapeutic target[1][2][3][4]. By convention, most NATs—including this one—are not considered independent drug targets or therapeutic receptors, enzymes, or transporters, but rather as regulatory RNAs that might indirectly influence disease through modulation of protein-coding sense genes such as JAG2[2][4]. Note: The identity of "ENSG00000303831" is correct and matches Ensembl and GeneCards entries. This molecule is not a protein, does not encode a receptor or enzyme, and does not currently have recognized direct drug interactions or safety liabilities[1]. Caveats: - No information is available on specific disease involvement or suitability as a biomarker for this unique transcript. - No drugs are known to target this antisense transcript specifically, though emerging research in antisense RNA therapy targets the class as a whole[3]. - The term "therapeutic target" does not currently apply to this NAT in a classical pharmacological sense[3][4].

Other names

Novel transcript antisense to JAG2ENSG00000303831